Howard S Hochster, Associate Director for Clinical Research at Rutgers Cancer Institute of New Jersey, shared a post on X:
“Interesting phase 3 data on intraperitoneal therapy from China GI25. Soon to be studied in EAONC STOPGAP study. Study lead by Dr Brett Ecker, Rutgers Cancer Institute soon.”
